{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T15:58:48Z","timestamp":1792166328564,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Korean Fund for Regenerative Medicine","award":["23A0106L1"],"award-info":[{"award-number":["23A0106L1"]}]},{"name":"Korean Fund for Regenerative Medicine","award":["23A0106L1"],"award-info":[{"award-number":["23A0106L1"]}]},{"name":"Korean Fund for Regenerative Medicine","award":["23A0106L1"],"award-info":[{"award-number":["23A0106L1"]}]},{"name":"Korean Fund for Regenerative Medicine","award":["23A0106L1"],"award-info":[{"award-number":["23A0106L1"]}]},{"name":"Korean Fund for Regenerative Medicine","award":["23A0106L1"],"award-info":[{"award-number":["23A0106L1"]}]},{"name":"Korean Fund for Regenerative Medicine","award":["23A0106L1"],"award-info":[{"award-number":["23A0106L1"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01730-1","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T10:37:23Z","timestamp":1763030243000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Directly reprogrammed NK cells driven by BCL11B depletion enhance targeted immunotherapy against pancreatic ductal adenocarcinoma"],"prefix":"10.1186","volume":"18","author":[{"given":"Han-Seop","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Yun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Young","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binna","family":"Seol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Eun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee Sook","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"issue":"1","key":"1730_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"1730_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM. Pancreatic cancer: A review. JAMA. 2021;326(9):851\u201362.","journal-title":"JAMA"},{"issue":"9","key":"1730_CR3","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1136\/gutjnl-2015-309304","volume":"64","author":"A Neesse","year":"2015","unstructured":"Neesse A, Algul H, Tuveson DA, Gress TM. Stromal biology and therapy in pancreatic cancer: a changing paradigm. Gut. 2015;64(9):1476\u201384.","journal-title":"Gut"},{"issue":"3\u20134","key":"1730_CR4","doi-asserted-by":"publisher","first-page":"78","DOI":"10.18632\/genesandcancer.171","volume":"9","author":"A Cannon","year":"2018","unstructured":"Cannon A, Thompson C, Hall BR, Jain M, Kumar S, Batra SK. Desmoplasia in pancreatic ductal adenocarcinoma: insight into pathological function and therapeutic potential. Genes Cancer. 2018;9(3\u20134):78\u201386.","journal-title":"Genes Cancer"},{"issue":"11","key":"1730_CR5","doi-asserted-by":"publisher","first-page":"101248","DOI":"10.1016\/j.xcrm.2023.101248","volume":"4","author":"S Mascharak","year":"2023","unstructured":"Mascharak S, Guo JL, Foster DS, Khan A, Davitt MF, Nguyen AT, Burcham AR, Chinta MS, Guardino NJ, Griffin M, et al. Desmoplastic stromal signatures predict patient outcomes in pancreatic ductal adenocarcinoma. Cell Rep Med. 2023;4(11):101248.","journal-title":"Cell Rep Med"},{"key":"1730_CR6","doi-asserted-by":"crossref","unstructured":"Huber M, Brehm CU, Gress TM, Buchholz M, Alashkar Alhamwe B, von Strandmann EP, Slater EP, Bartsch JW, Bauer C, Lauth M. The Immune Microenvironment in Pancreatic Cancer. Int J Mol Sci 2020, 21(19).","DOI":"10.3390\/ijms21197307"},{"key":"1730_CR7","doi-asserted-by":"publisher","first-page":"106898","DOI":"10.1016\/j.imlet.2024.106898","volume":"269","author":"S Carlomagno","year":"2024","unstructured":"Carlomagno S, Setti C, Ortolani F, Sivori S. Pancreatic ductal adenocarcinoma microenvironment: soluble factors and cancer associated fibroblasts as modulators of NK cell functions. Immunol Lett. 2024;269:106898.","journal-title":"Immunol Lett"},{"issue":"8","key":"1730_CR8","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1093\/annonc\/mdw168","volume":"27","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, Marabelle A, Eggermont A, Soria JC, Kroemer G, Zitvogel L. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482\u201392.","journal-title":"Ann Oncol"},{"issue":"10","key":"1730_CR9","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","volume":"22","author":"TJ Laskowski","year":"2022","unstructured":"Laskowski TJ, Biederstadt A, Rezvani K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer. 2022;22(10):557\u201375.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1730_CR10","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.gendis.2022.07.009","volume":"10","author":"L Wang","year":"2023","unstructured":"Wang L, Chen Z, Liu G, Pan Y. Functional crosstalk and regulation of natural killer cells in tumor microenvironment: significance and potential therapeutic strategies. Genes Dis. 2023;10(3):990\u20131004.","journal-title":"Genes Dis"},{"issue":"34","key":"1730_CR11","doi-asserted-by":"publisher","first-page":"56968","DOI":"10.18632\/oncotarget.18185","volume":"8","author":"JRM Van Audenaerde","year":"2017","unstructured":"Van Audenaerde JRM, De Waele J, Marcq E, Van Loenhout J, Lion E, Van den Bergh JMJ, Jesenofsky R, Masamune A, Roeyen G, Pauwels P, et al. Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells. Oncotarget. 2017;8(34):56968\u201379.","journal-title":"Oncotarget"},{"key":"1730_CR12","doi-asserted-by":"crossref","unstructured":"Li W, Wang X, Zhang X, Aziz AUR, Wang D. CAR-NK cell therapy: A transformative approach to overcoming oncological challenges. Biomolecules 2024, 14(8).","DOI":"10.3390\/biom14081035"},{"issue":"11","key":"1730_CR13","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1038\/s41551-021-00768-z","volume":"5","author":"HS Kim","year":"2021","unstructured":"Kim HS, Kim JY, Seol B, Song CL, Jeong JE, Cho YS. Directly reprogrammed natural killer cells for cancer immunotherapy. Nat Biomed Eng. 2021;5(11):1360\u201376.","journal-title":"Nat Biomed Eng"},{"issue":"5987","key":"1730_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1126\/science.1188063","volume":"329","author":"P Li","year":"2010","unstructured":"Li P, Burke S, Wang J, Chen X, Ortiz M, Lee SC, Lu D, Campos L, Goulding D, Ng BL, et al. Reprogramming of T cells to natural killer-like cells upon Bcl11b deletion. Science. 2010;329(5987):85\u20139.","journal-title":"Science"},{"issue":"1","key":"1730_CR15","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1600-065X.2010.00953.x","volume":"238","author":"P Liu","year":"2010","unstructured":"Liu P, Li P, Burke S. Critical roles of Bcl11b in T-cell development and maintenance of T-cell identity. Immunol Rev. 2010;238(1):138\u201349.","journal-title":"Immunol Rev"},{"key":"1730_CR16","doi-asserted-by":"publisher","first-page":"1146077","DOI":"10.3389\/fimmu.2023.1146077","volume":"14","author":"AA Korchagina","year":"2023","unstructured":"Korchagina AA, Shein SA, Koroleva E, Tumanov AV. Transcriptional control of ILC identity. Front Immunol. 2023;14:1146077.","journal-title":"Front Immunol"},{"issue":"2","key":"1730_CR17","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1158\/1541-7786.MCR-19-0688","volume":"18","author":"LR Avula","year":"2020","unstructured":"Avula LR, Rudloff M, El-Behaedi S, Arons D, Albalawy R, Chen X, Zhang X, Alewine C. Mesothelin enhances tumor vascularity in newly forming pancreatic peritoneal metastases. Mol Cancer Res. 2020;18(2):229\u201339.","journal-title":"Mol Cancer Res"},{"issue":"4","key":"1730_CR18","doi-asserted-by":"publisher","first-page":"422","DOI":"10.7150\/ijms.39012","volume":"17","author":"K Le","year":"2020","unstructured":"Le K, Wang J, Zhang T, Guo Y, Chang H, Wang S, Zhu B. Overexpression of mesothelin in pancreatic ductal adenocarcinoma (PDAC). Int J Med Sci. 2020;17(4):422\u20137.","journal-title":"Int J Med Sci"},{"key":"1730_CR19","doi-asserted-by":"publisher","first-page":"110901","DOI":"10.1016\/j.cbi.2024.110901","volume":"391","author":"K Tomovic Pavlovic","year":"2024","unstructured":"Tomovic Pavlovic K, Kocic G, Smelcerovic A. Myt1 kinase inhibitors - Insight into structural features, offering potential frameworks. Chem Biol Interact. 2024;391:110901.","journal-title":"Chem Biol Interact"},{"key":"1730_CR20","doi-asserted-by":"crossref","unstructured":"Korbecki J, Siminska D, Kojder K, Grochans S, Gutowska I, Chlubek D, Baranowska-Bosiacka I. Fractalkine\/CX3CL1 in neoplastic processes. Int J Mol Sci 2020, 21(10).","DOI":"10.3390\/ijms21103723"},{"issue":"41","key":"1730_CR21","doi-asserted-by":"publisher","first-page":"6228","DOI":"10.2174\/0929867329666220629140540","volume":"29","author":"X Lu","year":"2022","unstructured":"Lu X. Structure and function of ligand CX3CL1 and its receptor CX3CR1 in cancer. Curr Med Chem. 2022;29(41):6228\u201346.","journal-title":"Curr Med Chem"},{"issue":"6","key":"1730_CR22","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1016\/j.stemcr.2017.04.011","volume":"8","author":"HS Kim","year":"2017","unstructured":"Kim HS, Lee J, Lee DY, Kim YD, Kim JY, Lim HJ, Lim S, Cho YS. Schwann cell precursors from human pluripotent stem cells as a potential therapeutic target for Myelin repair. Stem Cell Rep. 2017;8(6):1714\u201326.","journal-title":"Stem Cell Rep"},{"key":"1730_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/978-1-4939-9728-2_12","volume":"2048","author":"H Zhu","year":"2019","unstructured":"Zhu H, Kaufman DS. An improved method to produce Clinical-Scale natural killer cells from human pluripotent stem cells. Methods Mol Biol. 2019;2048:107\u201319.","journal-title":"Methods Mol Biol"},{"issue":"6421","key":"1730_CR24","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1126\/science.aas9090","volume":"362","author":"M Ruscetti","year":"2018","unstructured":"Ruscetti M, Leibold J, Bott MJ, Fennell M, Kulick A, Salgado NR, Chen CC, Ho YJ, Sanchez-Rivera FJ, Feucht J, et al. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science. 2018;362(6421):1416\u201322.","journal-title":"Science"},{"issue":"12","key":"1730_CR25","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li W, Xu H, Xiao T, Cong L, Love MI, Zhang F, Irizarry RA, Liu JS, Brown M, Liu XS. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 2014;15(12):554.","journal-title":"Genome Biol"},{"key":"1730_CR26","doi-asserted-by":"publisher","first-page":"107637","DOI":"10.1016\/j.phrs.2025.107637","volume":"212","author":"Y Ren","year":"2025","unstructured":"Ren Y, Xue M, Hui X, Liu X, Farooq MA, Chen Y, Ji Y, Duan Y, Ajmal I, Yao J, et al. Chimeric cytokine receptor TGF-beta RII\/IL-21R improves CAR-NK cell function by reversing the immunosuppressive tumor microenvironment of gastric cancer. Pharmacol Res. 2025;212:107637.","journal-title":"Pharmacol Res"},{"key":"1730_CR27","doi-asserted-by":"publisher","first-page":"849493","DOI":"10.3389\/fimmu.2022.849493","volume":"13","author":"X Wu","year":"2022","unstructured":"Wu X, Xiao Y, Guo D, Zhang Z, Liu M. Reduced NK cell cytotoxicity by Papillomatosis-Derived TGF-beta contributing to Low-Risk HPV persistence in JORRP patients. Front Immunol. 2022;13:849493.","journal-title":"Front Immunol"},{"issue":"21","key":"1730_CR28","doi-asserted-by":"publisher","first-page":"e113448","DOI":"10.15252\/embj.2023113448","volume":"42","author":"R Liao","year":"2023","unstructured":"Liao R, Wu Y, Qin L, Jiang Z, Gou S, Zhou L, Hong Q, Li Y, Shi J, Yao Y, et al. BCL11B and the NuRD complex cooperatively guard T-cell fate and inhibit OPA1-mediated mitochondrial fusion in T cells. EMBO J. 2023;42(21):e113448.","journal-title":"EMBO J"},{"issue":"1","key":"1730_CR29","doi-asserted-by":"publisher","first-page":"2148850","DOI":"10.1080\/2162402X.2022.2148850","volume":"11","author":"H Forkel","year":"2022","unstructured":"Forkel H, Grabarczyk P, Depke M, Troschke-Meurer S, Simm S, Hammer E, Michalik S, Hentschker C, Corleis B, Loyal L, et al. BCL11B depletion induces the development of highly cytotoxic innate T cells out of IL-15 stimulated peripheral blood alphabeta CD8\u2009+\u2009T cells. Oncoimmunology. 2022;11(1):2148850.","journal-title":"Oncoimmunology"},{"issue":"12","key":"1730_CR30","doi-asserted-by":"publisher","first-page":"5108","DOI":"10.1172\/JCI126350","volume":"129","author":"M Maluski","year":"2019","unstructured":"Maluski M, Ghosh A, Herbst J, Scholl V, Baumann R, Huehn J, Geffers R, Meyer J, Maul H, Eiz-Vesper B, et al. Chimeric antigen receptor-induced BCL11B suppression propagates NK-like cell development. J Clin Invest. 2019;129(12):5108\u201322.","journal-title":"J Clin Invest"},{"issue":"63","key":"1730_CR31","doi-asserted-by":"publisher","first-page":"eabe6968","DOI":"10.1126\/sciimmunol.abe6968","volume":"6","author":"R Sottile","year":"2021","unstructured":"Sottile R, Panjwani MK, Lau CM, Daniyan AF, Tanaka K, Barker JN, Brentjens RJ, Sun JC, Le Luduec JB, Hsu KC. Human cytomegalovirus expands a CD8(+) T cell population with loss of BCL11B expression and gain of NK cell identity. Sci Immunol. 2021;6(63):eabe6968.","journal-title":"Sci Immunol"},{"issue":"1","key":"1730_CR32","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40364-022-00358-4","volume":"10","author":"Z Jiang","year":"2022","unstructured":"Jiang Z, Qin L, Tang Y, Liao R, Shi J, He B, Li S, Zheng D, Cui Y, Wu Q, et al. Human induced-T-to-natural killer cells have potent anti-tumour activities. Biomark Res. 2022;10(1):13.","journal-title":"Biomark Res"},{"issue":"6","key":"1730_CR33","doi-asserted-by":"publisher","first-page":"e322","DOI":"10.1111\/bjh.17010","volume":"190","author":"L Silla","year":"2020","unstructured":"Silla L. Double-bright (CD56bright\/CD16bright) natural killer cell adoptive immunotherapy for SARS-CoV-2. Br J Haematol. 2020;190(6):e322\u20133.","journal-title":"Br J Haematol"},{"issue":"5","key":"1730_CR34","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/bjh.17751","volume":"195","author":"L Silla","year":"2021","unstructured":"Silla L, Valim V, Pezzi A, da Silva M, Wilke I, Nobrega J, Vargas A, Amorin B, Correa B, Zambonato B, et al. Adoptive immunotherapy with double-bright (CD56(bright) \/CD16(bright)) expanded natural killer cells in patients with relapsed or refractory acute myeloid leukaemia: a proof-of-concept study. Br J Haematol. 2021;195(5):710\u201321.","journal-title":"Br J Haematol"},{"key":"1730_CR35","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3389\/fimmu.2017.00699","volume":"8","author":"M Amand","year":"2017","unstructured":"Amand M, Iserentant G, Poli A, Sleiman M, Fievez V, Sanchez IP, Sauvageot N, Michel T, Aouali N, Janji B, et al. Human CD56(dim)CD16(dim) cells as an individualized natural killer cell subset. Front Immunol. 2017;8:699.","journal-title":"Front Immunol"},{"key":"1730_CR36","doi-asserted-by":"publisher","first-page":"156455","DOI":"10.1016\/j.cyto.2023.156455","volume":"174","author":"LM Saito","year":"2024","unstructured":"Saito LM, Ortiz RC, Amor NG, Lopes NM, Buzo RF, Garlet GP, Rodini CO. NK cells and the profile of inflammatory cytokines in the peripheral blood of patients with advanced carcinomas. Cytokine. 2024;174:156455.","journal-title":"Cytokine"},{"issue":"4","key":"1730_CR37","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1365-2567.2008.03027.x","volume":"126","author":"A Poli","year":"2009","unstructured":"Poli A, Michel T, Theresine M, Andres E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126(4):458\u201365.","journal-title":"Immunology"},{"issue":"4","key":"1730_CR38","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.cell.2020.01.022","volume":"180","author":"P Dogra","year":"2020","unstructured":"Dogra P, Rancan C, Ma W, Toth M, Senda T, Carpenter DJ, Kubota M, Matsumoto R, Thapa P, Szabo PA, et al. Tissue determinants of human NK cell development, function, and residence. Cell. 2020;180(4):749\u2013e763713.","journal-title":"Cell"},{"key":"1730_CR39","doi-asserted-by":"publisher","first-page":"888313","DOI":"10.3389\/fimmu.2022.888313","volume":"13","author":"D Corvino","year":"2022","unstructured":"Corvino D, Kumar A, Bald T. Plasticity of NK cells in cancer. Front Immunol. 2022;13:888313.","journal-title":"Front Immunol"},{"issue":"12","key":"1730_CR40","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.4049\/jimmunol.1900985","volume":"203","author":"AR Temming","year":"2019","unstructured":"Temming AR, de Taeye SW, de Graaf EL, de Neef LA, Dekkers G, Bruggeman CW, Koers J, Ligthart P, Nagelkerke SQ, Zimring JC, et al. Functional attributes of antibodies, effector cells, and target cells affecting NK Cell-Mediated Antibody-Dependent cellular cytotoxicity. J Immunol. 2019;203(12):3126\u201335.","journal-title":"J Immunol"},{"issue":"1","key":"1730_CR41","doi-asserted-by":"publisher","first-page":"2233402","DOI":"10.1080\/2162402X.2023.2233402","volume":"12","author":"D Brownlie","year":"2023","unstructured":"Brownlie D, von Kries A, Valenzano G, Wild N, Yilmaz E, Safholm J, Al-Ameri M, Alici E, Ljunggren HG, Schliemann I, et al. Accumulation of tissue-resident natural killer cells, innate lymphoid cells, and CD8(+) T cells towards the center of human lung tumors. Oncoimmunology. 2023;12(1):2233402.","journal-title":"Oncoimmunology"},{"key":"1730_CR42","doi-asserted-by":"publisher","first-page":"105176","DOI":"10.1016\/j.ebiom.2024.105176","volume":"104","author":"JKM Wong","year":"2024","unstructured":"Wong JKM, McCulloch TR, Alim L, Omer N, Mehdi AM, Tuong ZK, Bonfim-Melo A, Chung E, Nicol A, Simpson F, et al. TGF-beta signalling limits effector function capacity of NK cell anti-tumour immunity in human bladder cancer. EBioMedicine. 2024;104:105176.","journal-title":"EBioMedicine"},{"key":"1730_CR43","doi-asserted-by":"publisher","first-page":"122888","DOI":"10.1016\/j.biomaterials.2024.122888","volume":"314","author":"SH Shin","year":"2025","unstructured":"Shin SH, Lee YE, Yoon HN, Yuk CM, An JY, Seo M, Yoon S, Oh MS, Shin SC, Kim JH, et al. An innovative strategy Harnessing self-activating CAR-NK cells to mitigate TGF-beta1-driven immune suppression. Biomaterials. 2025;314:122888.","journal-title":"Biomaterials"},{"issue":"1","key":"1730_CR44","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13045-024-01525-w","volume":"17","author":"A Van den Eynde","year":"2024","unstructured":"Van den Eynde A, Gehrcken L, Verhezen T, Lau HW, Hermans C, Lambrechts H, Flieswasser T, Quatannens D, Roex G, Zwaenepoel K, et al. IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts. J Hematol Oncol. 2024;17(1):8.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"1730_CR45","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1053\/j.gastro.2021.12.281","volume":"162","author":"KY Teng","year":"2022","unstructured":"Teng KY, Mansour AG, Zhu Z, Li Z, Tian L, Ma S, Xu B, Lu T, Chen H, Hou D, et al. Off-the-Shelf prostate stem cell antigen-Directed chimeric antigen receptor natural killer cell therapy to treat pancreatic cancer. Gastroenterology. 2022;162(4):1319\u201333.","journal-title":"Gastroenterology"},{"issue":"6908","key":"1730_CR46","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/nature01112","volume":"419","author":"V Groh","year":"2002","unstructured":"Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419(6908):734\u20138.","journal-title":"Nature"},{"key":"1730_CR47","doi-asserted-by":"crossref","unstructured":"Esposito F, Giuffrida R, Raciti G, Puglisi C, Forte S. Wee1 Kinase: A Potential Target to Overcome Tumor Resistance to Therapy. Int J Mol Sci 2021, 22(19).","DOI":"10.3390\/ijms221910689"},{"issue":"1","key":"1730_CR48","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1002\/mc.23643","volume":"63","author":"M Wang","year":"2024","unstructured":"Wang M, Zhang C, Ying Y, Hua M, Meng F, Wang Z, Liu A, Zeng S, Zhang Z, Xu C. PKMYT1 induced by YAP\/TEAD1 gives rise to the progression and worse prognosis of bladder cancer. Mol Carcinog. 2024;63(1):160\u201372.","journal-title":"Mol Carcinog"},{"key":"1730_CR49","doi-asserted-by":"publisher","first-page":"e17749","DOI":"10.7717\/peerj.17749","volume":"12","author":"W Gao","year":"2024","unstructured":"Gao W, Guo X, Sun L, Gai J, Cao Y, Zhang S. PKMYT1 knockdown inhibits cholesterol biosynthesis and promotes the drug sensitivity of triple-negative breast cancer cells to Atorvastatin. PeerJ. 2024;12:e17749.","journal-title":"PeerJ"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01730-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01730-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01730-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:02:50Z","timestamp":1763035370000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01730-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1730"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01730-1","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}}],"article-number":"100"}}